Samsung Shares Dip Amid Tech Sector Pressure; AI Trade Momentum in Focus
Markets Daniel Marsh

Samsung Shares Dip Amid Tech Sector Pressure; AI Trade Momentum in Focus

Samsung Electronics closed slightly lower Friday as broader tech weakness weighed on Seoul markets. Investors are assessing chip demand and AI-driven trades ahead of next week's key events.

SSNLF
Berkshire Hathaway Shares Close Above $508 as Dow Surpasses 50,000 Milestone
Markets Daniel Marsh

Berkshire Hathaway Shares Close Above $508 as Dow Surpasses 50,000 Milestone

Berkshire Hathaway's Class B stock advanced 0.83% to $508.09 on Friday, with the broader market rallying as the Dow Jones Industrial Average closed above 50,000 for the first time.

BRK.B
TSMC Shares Rally as Semiconductor Sector Rebounds Ahead of Key Sales Data
Markets Daniel Marsh

TSMC Shares Rally as Semiconductor Sector Rebounds Ahead of Key Sales Data

TSMC's U.S.-listed shares surged over 5% Friday amid a broad semiconductor rally. Investors await the company's January sales report on February 10 for early signals on chip demand.

TSM AMD AVGO NVDA
Strive Asset Management Shares Rally Following Reverse Stock Split Implementation
Markets Daniel Marsh

Strive Asset Management Shares Rally Following Reverse Stock Split Implementation

Strive Asset Management's stock surged over 20% Friday after a 1-for-20 reverse split took effect, with trading volume reaching 9.36 million shares. Investors are now monitoring post-split liquidity and the performance of the company's preferred shares.

ASST
Applied Digital Surges 25% Amid AI Infrastructure Rebound
Technology Sarah Chen

Applied Digital Surges 25% Amid AI Infrastructure Rebound

Applied Digital shares soared 25% Friday following a 250% revenue jump and new data center leases, as AI-related stocks recover.

APLD
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Regulation James Calloway

FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares

Eli Lilly stock gained 3.7% after FDA signaled action against telehealth firm Hims & Hers over $49 compounded weight-loss alternatives. Regulatory uncertainty continues to impact obesity drug market valuations.

LLY